Lonza Doubles Down on U.S. Manufacturing with Multi Site Merck CDMO Buyout - GeneOnline News
Lonza has agreed to acquire Merck KGaA's U.S. contract manufacturing network for CHF 100-600M, expanding its U.S. footprint from 4 to 9 sites and adding 1,100 employees. The deal aims to meet North American demand for advanced therapies and reduce supply chain risks. Lonza expects the acquired network to generate CHF 250M in annual sales by 2028, with margins improving by the mid-2030s.
How this was made
The 30-second read
Why it matters
Both companies aim to sharpen portfolios: Lonza expands capacity, Merck focuses on high‑margin tools.
Market read
First‑report M&A in the biotech CDMO space with moderate scale, likely influencing sector valuations and supply‑chain strategies.
What to watch
Regulatory approvals and potential antitrust review could delay closing, affecting timing of anticipated benefits.
Background
The deal reflects growing demand for domestic biopharma manufacturing amid geopolitical trade friction and supply‑chain concerns.
Market effects
Strengthens the U.S. CDMO sector by consolidating capacity under Lonza, potentially raising competitive pressure on other contract manufacturers.
Boosts U.S. biopharma supply chain resilience, reducing reliance on overseas facilities.
Highlights a trend of nearshoring in biotech manufacturing, relevant for global investors tracking pharma supply‑chain dynamics.
Counterpoint
The integration risk and capital outlay could strain Lonza's margins if synergies are slower than expected.
Key entities
- CompanyLonza Group AG
Swiss contract development and manufacturing organization expanding U.S. footprint.
- CompanyMerck KGaA
German life‑science tools and chemicals company exiting U.S. CDMO business.
